AbbVie Inc. (ABBV)

78.58
1.30 1.70
NYSE : Health Technology
Prev Close 77.30
Open 78.05
Day Low/High 77.75 / 78.42
52 Wk Low/High 62.66 / 94.98
Volume 948.12K
Avg Volume 8.53M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 113.04B
EPS 3.70
P/E Ratio 27.21
Div & Yield 4.28 (5.55%)
There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

The ECB's super dovish message was good for the markets.

Alphabet, Amazon and Expedia: This Is What You Must Know on Friday

Alphabet, Amazon and Expedia: This Is What You Must Know on Friday

U.S. futures point a higher open following earnings beats from Amazon, Alphabet and Microsoft after the bell on Thursday.

AbbVie Is Likely to Correct: Book Some Profits

AbbVie Is Likely to Correct: Book Some Profits

ABBV has gone 'vertical' on the daily chart.

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

AbbVie Reaches All-Time Highs

AbbVie Reaches All-Time Highs

Today's breakout could carry the stock sharply higher.

Earnings: Assessing 3 Biotech Bellwethers

Earnings: Assessing 3 Biotech Bellwethers

How did Celgene, AbbVie and Gilead fare last quarter?

Cramer: When Oil Falls, These Dominoes Get Hit

Cramer: When Oil Falls, These Dominoes Get Hit

It doesn't look like Washington will be much help.

AbbVie Is Flexing Its Abs

AbbVie Is Flexing Its Abs

ABBV is now set up well for more upside.

A Trio of Stocks Up on Nice Results

The market is off to a decent start as investors try to digest scores of first-quarter earnings reports. Bristol-Myers Squibb is just one of many large-cap drug and biotech companies reporting today. BMY shares are up as earnings and revenue easily ...

Early-Morning Earnings Extravaganza

It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Streamlined FDA Approval Process Would Boost Drug Makers

Streamlined FDA Approval Process Would Boost Drug Makers

Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie

Novice Trade: AbbVie

Getting FDA to streamline its approval process would boost drug makers.

Trump Investing: Listen, Don't Overreact

Trump Investing: Listen, Don't Overreact

Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.

Create a 'Barbell' of Value, Income Stocks

Create a 'Barbell' of Value, Income Stocks

Value stocks will extend their outperformance over growth stocks that began last year.

What to Watch Friday: American Airlines Earnings, Fourth-Quarter GDP

What to Watch Friday: American Airlines Earnings, Fourth-Quarter GDP

On Friday, investors will get quarterly results from American Airlines and the release of fourth quarter gross domestic product.

Biotech Sector to See M&A, Earnings Action

Biotech Sector to See M&A, Earnings Action

Deals already are popping up, and we'll soon have earnings reports from the industry giants.

Biotech Just Got Trumped

Biotech Just Got Trumped

But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.

Top 5 Dividend Stocks to Buy Now for 2017

Top 5 Dividend Stocks to Buy Now for 2017

Here is a look at some stocks that are poised for excellent dividend returns in 2017.

Expect Some Big-Cap Biotech Love in 2017

We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...

AbbVie Needs a Nudge to Get the Bull Going Again

AbbVie Needs a Nudge to Get the Bull Going Again

Overall, the next move for ABBV looks like it will be to the upside.

Some Black Friday Stock Market Buys

Bullish and Bearish Chart Reversals

Bullish and Bearish Chart Reversals

What stocks have changed direction in the past week.

How to Play Rising Treasury Yields

How to Play Rising Treasury Yields

Check out these 15 stocks that boast solid dividend yields and are growing earnings.